lobbying_activities: 1145040
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1145040 | 5d0d2636-3759-469e-9a9c-e1cc1e24ce38 | Q3 | MEHLMAN CONSULTING, INC. | 284950 | ASTRAZENECA PHARMACEUTICALS | 2011 | third_quarter | MMM | Budget issues, including Medicare Part D Rebates. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package. Health reform implementation. Independent Payment Advisory Board. Budget Control Act of 2011 (Became PL 112-25 on August 2, 2011) | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2011-10-05T15:37:05.503000-04:00 |